DOXO-EMCH 是 Doxorubicin 的衍生物,为白蛋白结合前体药物。
Description | DOXO-EMCH is a 6-maleimidocaproyl hydrazone derivative of Doxorubicin, is an albumin binding prodrug. | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
| ||||||||||||||||
In Vitro | DOXO-EMCH is an an acid-sensitive prodrug of Doxorubicin that binds rapidly and selectively to the cysteine-34 position of circulating albumin[1]. | ||||||||||||||||
In Vivo | DOXO-EMCH is a 6-maleimidocaproyl hydrazone derivative of Doxorubicin. DOXO-EMCH unlike its free Doxorubicin parent, achieves complete remissions in a murine renal cell carcinoma model and in 2 breast carcinoma xenograft models. Moreover, DOXO-EMCH is also superior to Doxorubicin with regard to drug toxicity in mice, rats and dogs, and exhibits a good safety profile[2]. | ||||||||||||||||
Solvent & Solubility | In Vitro: 10 mM in DMSO Preparing Stock Solutions
* Please refer to the solubility information to select the appropriate solvent. In Vivo:
| ||||||||||||||||
References | |
温馨提示:因厂家更改产品包装、产地或者更换随机附件等没有任何提前通知,且每位咨询者购买情况、提问时间等不同,为此以下回复仅对提问者3天内有效,其他网友仅供参考!若由此给您带来不便请多多谅解,谢谢!
服务热线
0771-3293894